Merck & Company
2000 Galloping Hill Road
About Merck & Company
Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
2838 articles with Merck & Company
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
Application Based on Overall Survival and Progression-Free Survival Data from Phase 3 KEYNOTE-426 Trial
Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
Research Program Expanded Based on Promising Data Shown with KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib), Chemotherapy and Anti-Hormone Agents in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The pharma giant announced plans to expand its immuno-oncology program with three new Phase III trials following promising data from a combination of Keytruda and Lynparza and other agents.
Lawmakers continue to hear concerns over drug prices, as well as proposals to fix the issue.
The American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) is being held in San Francisco from February 14-16. Ahead of the conference, several companies have announced presentations. Here’s a look at just a few.
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Filing Includes Use of KEYTRUDA in the First-Line Setting as Monotherapy or in Combination with Chemotherapy
First-Time Data from Pivotal Phase 3 KEYNOTE-426 Trial Showing KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Significantly Improved OS, PFS and ORR Compared to Sunitinib Monotherapy in First-Line Treatment of Advanced Renal Cell Carcinoma
It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods.
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the pro...
FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam)
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review regulatory filings for two antibacterial agents.
European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Recommendation Based on Significant Overall Survival Benefit Demonstrated with KEYTRUDA in Combination with Chemotherapy in Pivotal KEYNOTE-407 Trial
Over the next two weeks, the U.S. Food and Drug Administration (FDA) has three upcoming decisions. Here’s a look.
Fourth-Quarter 2018 Worldwide Sales Were $11.0 Billion, an Increase of 5 Percent, Including a 3 Percent Negative Impact from Foreign Exchange; Full-Year 2018 Worldwide Sales Were $42.3 Billion, an Increase of 5 Percent, Including a Minimal Impact from Foreign Exchange
2/1/2019Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s a theme among them, it seems lower earnings per share are forecast for the year.
Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents
Merc that V114 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of invasive pneumococcal disease caused by the vaccine serotypes in pediatric patients 6 weeks to 18 years of age.
Merck, known as MSD outside the United States and Canada, announced that Mary Ellen Coe, president, Google Customer Solutions, at Google Inc. will join the company’s Board of Directors effective March 18, 2019.
Merck, known as MSD outside the United States and Canada, announced that the Board of Directors has declared a quarterly dividend of $0.55 per share of the company’s common stock for the second quarter of 2019.
U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate)
Potential New Indication Would Expand Use to Allow Treatment-Experienced Adults Living with HIV-1 Whose Virus is Suppressed to Switch to PIFELTRO (in Combination with Other Antiretrovirals) or DELSTRIGO
Merck will hold its fourth-quarter and full-year 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Friday, Feb. 1.
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.